Cargando…
Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways
Anlotinib is a novel multi-targeted tyrosine kinase inhibitor with activity against soft tissue sarcoma, small cell lung cancer, and non-small cell lung cancer (NSCLC). Potentiating the anticancer effect of anlotinib in combination strategies remains a clinical challenge. Metformin is an oral agent...
Autores principales: | Zhu, Zhongling, Jiang, Teng, Suo, Huirong, Xu, Shan, Zhang, Cai, Ying, Guoguang, Yan, Zhao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373262/ https://www.ncbi.nlm.nih.gov/pubmed/34421608 http://dx.doi.org/10.3389/fphar.2021.712181 |
Ejemplares similares
-
Metformin Attenuates Silica-Induced Pulmonary Fibrosis by Activating Autophagy via the AMPK-mTOR Signaling Pathway
por: Li, Shu-xian, et al.
Publicado: (2021) -
Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway
por: Li, Liuran, et al.
Publicado: (2021) -
The protective roles of allicin on type 1 diabetes mellitus through AMPK/mTOR mediated autophagy pathway
por: Qian, Rengcheng, et al.
Publicado: (2023) -
Metformin attenuates cartilage degeneration in an experimental osteoarthritis model by regulating AMPK/mTOR
por: Feng, Xiaofeng, et al.
Publicado: (2020) -
Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
por: Renna, Maurizio
Publicado: (2016)